Solventum stock price target raised to $94 by Piper Sandler on strong Q2

Piper Sandler raised its price target on Solventum (NYSE:SOLV) to $94 from $87, maintaining an Overweight rating, following the healthcare company's strong second-quarter results. Solventum reported Q2 revenue of $2.161 billion (2.8% organic growth) and EPS of $1.69, surpassing consensus expectations. This upgrade reflects Piper Sandler's confidence in Solventum's improved execution and management's updated full-year guidance reflecting the outperformance, signaling potential for continued earnings growth and shareholder value creation, particularly with anticipated debt reduction.

Analysis

Piper Sandler has raised its price target for Solventum (SOLV) to $94.00 from $87.00, maintaining an Overweight rating, in response to the company's strong second-quarter financial results. Solventum reported revenue of approximately $2.2 billion, reflecting organic growth between 2.8% and 3.9%, and delivered earnings per share of $1.69, which surpassed consensus expectations. This performance extends a track record of profitability, evidenced by a last-twelve-months EBITDA of $1.416 billion. The analyst action reflects growing confidence in management's execution, which was further supported by an upward revision to full-year guidance that incorporated the Q2 outperformance. Piper Sandler sees a clear pathway to shareholder value creation and anticipates further core earnings upside, with potential for positive estimate revisions driven by future debt reduction following a planned 'P&F sale'. While the current share price of $71.95 is below the new target, it sits within the broader analyst range of $73-$103, and the article notes that a separate quantitative screen did not identify SOLV as a top-tier undervalued opportunity.

Key Decisions for Investors

• Given the strong earnings beat, raised guidance, and a material price target increase from a covering analyst, investors could consider the current valuation an opportunity, as the stock is trading significantly below the new $94 target.
• Investors should closely monitor management's execution on deleveraging efforts, particularly related to the mentioned 'P&F sale', as this is flagged as a key catalyst for future positive earnings revisions and value unlocking.
• While the analyst commentary is bullish, the lack of a top-tier ranking from a quantitative screen suggests that investors might await further quarters of sustained operational improvement before building a full-sized position.